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Intracerebral hemorrhage (ICH) is a deadly and debilitating type of stroke,
caused by the rupture of cerebral blood vessels. To date, there are no
restorative interventions approved for use in ICH patients, highlighting a
critical unmet need. ICH shares some pathological features with other acute
brain injuries such as ischemic stroke (IS) and traumatic brain injury (TBI),
including the loss of brain tissue, disruption of the blood–brain barrier, and
activation of a potent inflammatory response. New biomaterials such as
hydrogels have been recently investigated for their therapeutic benefit in both
experimental IS and TBI, owing to their provision of architectural support for
damaged brain tissue and ability to deliver cellular and molecular therapies.
Conversely, research on the use of hydrogels for ICH therapy is still in its
infancy, with very few published reports investigating their therapeutic
potential. Here, the published use of hydrogels in experimental ICH is
commented upon and how approaches reported in the IS and TBI fields may
be applied to ICH research to inform the design of future therapies is
described. Unique aspects of ICH that are distinct from IS and TBI that should
be considered when translating biomaterial-based therapies between disease
models are also highlighted.
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Injury of brain tissue caused by internal
or external factors is a common feature
of stroke and head trauma. Brain injury
can be caused by blunt force, tissue is-
chemia, or hemorrhage, as observed in
traumatic brain injury (TBI), ischemic
stroke (IS), and intracerebral hemorrhage
(ICH), respectively.[1] Despite differences
in disease mechanisms, clinical impact,
and predicted outcomes, all three condi-
tions share common pathological features.
These shared characteristics can be ex-
ploited when investigating the translational
potential of tissue engineering therapeutics
for new clinical applications. The use of
hydrogels as bioactive scaffolds or thera-
peutic delivery vehicles has been widely
investigated in the field of IS and TBI but is
still in relative infancy for use in ICH. This
review is not intended to provide a compre-
hensive overview of the use of hydrogels in
acute brain injury, rather to briefly discuss
promising approaches that could be applied
to the nascent field of biomaterials in ICH. Recently, Love et al.
raised important questions concerning the use of biomaterials
for stroke therapy.[2] Here, we expand upon this by identifying
key themes from the extensive IS and TBI literature that can
inform regenerative medicine approaches specifically for ICH.
We briefly cover the commonalities of acute brain injury and
the unique considerations for ICH, discuss the experimental ap-
proaches used to date, and consider how methods from IS and
TBI studies may present opportunities to advance this emerging
field of ICH research.
2. Common Mechanisms of Acute Brain Injury
Acute brain injury alters the physiological architecture and func-
tion of the brain tissue, resulting in a pathology with clinical
symptoms. The common hallmarks characterizing disease pro-
gression during brain injury include the acute loss of brain tis-
sue and disruption of the blood–brain barrier (BBB).[1,3] Loss
of neural and vascular brain tissue can arise as a result of tis-
sue ischemia as observed in IS, following mechanical dam-
age downstream of hematoma and edema formation in ICH,
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Table 1. Differences in acute brain injury progression with possible impacts on hydrogel therapy design.
IS (blockage of cerebral blood
vessels)
TBI (trauma to the skull) ICH (rupture of cerebral blood
vessels)
Considerations for hydrogel therapy











Therapies may need to be
personalized based on underlying
health conditions affecting the
brain microarchitecture
Injury location Cortical and subcortical Predominantly cortical Cortical and subcortical,
subcortical more prevalent
Hydrogel therapies should be tailored
for brain regions with different cell
types and physical environments
Blood toxicity N/A unless hemorrhagic
transformation
+ +++ Hydrogels may need to be tailored to
reduce blood toxicity for ICH, e.g.,
by inclusion of iron chelators
Elevated ICP + + ++ Volume of hydrogel administered and











Chronic phase: shift to M1
(proinflammatory) microglia,
glial scar formation




Chronic phase: shift to M1
microglia, glial scar formation
Acute phase: reactive astrocytes,
mostly M1 microglia, infiltration
of inflammatory monocytes
Chronic phase: shift to M2
(reparative) microglia, glial scar
formation
Interactions of resident and
infiltrating cells with hydrogel
therapies should be considered,




+ + +/++ Depending on hematoma
aspiration
Volumes of hydrogel injection should
be compatible with cavity volume
or due to external forces to the skull after a contusion in TBI
(Table 1).[4,5]
Following initial tissue injury, secondary damage is caused by a
potent inflammatory response. Activation of the immune system
and a local inflammatory reaction is observed in all three types
of brain injury.[6–8] The inflammatory cascade is characterized by
activation of tissue-resident microglia and astrocytes, and infiltra-
tion of peripheral immune cells such as neutrophils, monocytes,
and macrophages.[9,10] Reactive astrocytes and microglia are re-
sponsible for the formation of a glial scar, which forms a border
around the injury site isolating it from healthy tissue to prevent
further damage. BBB integrity and water transport homeostasis
are markedly affected upon astrogliosis and microgliosis in the
glial scar, which trigger neurodegenerative as well as neuropro-
tective responses in these pathological conditions.[11]
Acute brain injury progression is further promoted by in-
flammatory cytokine cascades that exacerbate tissue loss and
functional impairment, resulting in sensorimotor and cognitive
deficits.[12–14] Patients may improve with rehabilitation and sup-
portive interventions; however, the brain is unable to fully repair
and recover to its preinjury state, leaving survivors of brain injury
with significant disabilities. This is a result of the poor regener-
ative capacity of the brain, despite the presence of endogenous
repair mechanisms such as neurogenesis where tissue-resident
neural stem cells (NSCs) are recruited from the subventricular
and subgranular neurogenic zones.[15,16] However, NSCs are of-
ten prevented from reaching the injury site by the impenetrable
glial scar or are insufficient in number to repopulate the lesion for
adequate recovery.[17] Additionally, neovascularization and blood
vessel remodeling occur in an attempt to restore the broken-down
BBB and re-establish blood flow to support the viability of the
newly repaired neural tissue.[1]
3. Unique Pathophysiological Features of ICH
Despite the numerous common features of acute brain injury,
there are some unique pathophysiological features of ICH, which
require consideration when designing an intracerebral hydrogel
treatment approach (Table 1). For instance, although edema is
common to all acute brain injuries and causes an acute and of-
ten detrimental increase in intracranial pressure (ICP), the addi-
tional presence of a hematoma in the parenchyma in ICH can
lead to dangerously sharp rises in ICP.[18] The hematoma occu-
pies space in the brain and elicits mass effects by compressing ad-
jacent tissues which can cause neurovascular unit dysfunction in-
cluding membrane depolarization and BBB disruption.[19,20] The
combined effect of brain swelling and mass effects on ICP are
prognostic of poorer outcomes and increased risk of mortality af-
ter ICH.[19,21]
Another distinct feature of ICH is the exposure of neural
tissue to blood and its degradation products. Thrombin and
hemoglobin breakdown products such as heme and iron are re-
leased into the parenchyma upon hemolysis and trigger a cascade
of secondary injury characterized by an exacerbated inflamma-
tory response, oxidative stress, excitotoxicity, and cell death.[22,23]
For instance, iron is thought to contribute to oxidative stress
through the generation of free radicals,[22] while thrombin is
known to cause BBB disruption and thus worsening of edema.[23]
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The unique features of ICH have been targeted in numerous pre-
clinical and clinical interventions to date, with limited success.
4. Clinical Interventions in ICH
Clinical and preclinical trials have attempted to address the
unmet clinical need in ICH. Nevertheless, ICH remains the
deadliest subtype of stroke with case fatality reaching 40%
after 1 month and 54% after a year.[20] Therapeutic strategies
investigated include pharmacological lowering of blood pressure
to prevent hematoma expansion[24,25] and administration of iron
chelators to reduce iron-induced toxicity.[26,27] Despite promising
preclinical results, to date, no pharmacological therapy has led
to any clinical benefit after ICH when compared to standard
medical care.[28]
A widely tested nonpharmacological therapeutic approach in
ICH is surgical evacuation of the hematoma, either by cran-
iotomy or minimally invasive surgery. Numerous active trials
including the DIST (Dutch Intracerebral Hemorrhage Trial,
NCT03608423), ENRICH (Early MiNimally invasive Removal of
IntraCerebral Hemorrhage, NCT02880878), and MIND (Artemis
in the Removal of Intracerebral Hemorrhage, NCT03342664)
are investigating the efficacy of minimally invasive hematoma
evacuation using specialized surgical technologies, with results
still awaited. Another trial exploring minimally invasive surgical
evacuation after ICH, the MISTIE III trial (Minimally Invasive
Surgery with Thrombolysis for Intracerebral Hemorrhage Evacu-
ation), was completed in 2019 and reported a neutral result of the
intervention on primary functional outcomes.[29] However, anal-
ysis of secondary outcomes suggested a modest improvement in
mortality rates among treated patients and the trial demonstrated
the safety of the surgical approach.[29] This may open the possibil-
ity of a dual-therapeutic approach combining surgical hematoma
aspiration with the delivery of a therapeutic agent to provide en-
hanced recovery.
5. Emerging Preclinical Therapies for ICH
Preclinical ICH studies have investigated a range of novel thera-
peutic approaches, including transplantation of cells and admin-
istration of exogenous growth factors or drugs. Many studies have
investigated the potential of mesenchymal stem cells (MSCs) as
agents to elicit protection and repair in ICH models, frequently
demonstrating improved functional recovery.[30] NSCs[31] and en-
dothelial progenitor cells (EPCs),[32] administered via direct in-
tracerebral implantation or intravenous infusion, have also been
studied as potential treatments in ICH due to their neurogenic
and angiogenic properties, respectively. It has been proposed that
the reparative effects observed following stem cell administration
may be due to their paracrine actions, as evidence shows poor
survival[33] and engraftment in the brain,[34] and marked accu-
mulation in the lungs following systemic administration.[35]
Recent studies have explored the use of acellular thera-
pies in ICH models, demonstrating positive impacts on func-
tional recovery. These include the administration of conditioned
medium, which contains factors released from cultured cells,[36]
and nanoscale membrane-bound extracellular vesicles that carry
cell-derived cargos to near and distant sites.[37,38] Other acellu-
lar therapies being investigated for ICH include the delivery of
growth factors such as fibroblast growth factor (FGF)[39] and
brain-derived neurotrophic factor (BDNF),[40] though persistence
of these factors in the brain is limited, with exogenous growth
factors diffusing into the cerebrospinal fluid within 12 h of in-
jection. Pharmaceutical agents such as curcumin target brain
edema by reducing BBB disruption following ICH,[41] with other
agents including dexamethasone, prostaglandin E2, and mela-
tonin also being explored.[42]
While these novel therapeutic approaches have proven benefi-
cial in animal models of ICH, the main barriers to clinical trans-
lation are the short retention time of cells and drugs in the brain
and limited contact with perihematomal tissue.[30] These issues
give rise to the potential need for repeated administration over
long-term recovery periods or incorporation in material-based
sustained release systems to improve bioavailability.
6. Hydrogels for Acute Brain Injury Repair
To address current limitations in cell and drug delivery, soft bio-
materials such as hydrogels have been considered for implanta-
tion at the ICH lesion site. Hydrogels are highly tunable materials
of different origins – natural, such as collagen[43] or hyaluronic
acid (HA)[44] hydrogels, and synthetic, such as self-assembling
peptide hydrogels (SAPHs).[45,46] Hydrogels are ideal candidates
for tissue regeneration as they can be engineered to mimic the
native extracellular matrix (ECM) and provide structural support
for repair processes.[47] They can also be functionalized with cell
adhesion motifs required for the attachment of transplanted cells
or endogenous brain cells recruited for regeneration.[46]
The use of hydrogels for repair following IS and TBI has been
extensively reviewed elsewhere and will not be covered in de-
tail here.[48–50] In general, for neural tissue applications, hydro-
gels should be biodegradable and tailored to match the brain
stiffness.[51]
The use of temporary scaffolds is desirable to initiate and sup-
port de novo tissue formation, however gradual degradation of
the hydrogel may lead to altered mechanical properties such as
a reduction in hydrogel stiffness. In vitro evidence suggests that
stiffer hydrogels favor the differentiation of neural progenitors
toward astrocytic lineages compared to softer substrates, which
promote neuronal differentiation.[52] The in vivo implantation of
hydrogels with stiffness exceeding that of normal brain tissue can
result in an exacerbated glial scar.[53] However, very soft gels with
fast degradation rates may not persist in situ for sufficient time
to allow brain tissue regeneration. Therefore, hydrogel stiffness
and degradation profile should be carefully considered to achieve
a balance between supporting regeneration and enabling rapid
clearance.
For minimally invasive administration, these hydrated mate-
rials need to be injectable and ideally gel in situ, in order to
fill irregularly shaped cavities resulting from injuries including
ICH.[45,47,54–56] Engineered hydrogels can release encapsulated
therapeutics in a sustained manner, and therefore prolong drug
presence around the target tissue, reducing the dose needed and
avoiding systemic side effects.[55,57] Hydrogels can also be used to
deliver cells into the ICH cavity,[58] enhancing cell survival by pre-
venting mechanical damage to cells upon injection[59] and provid-
ing a permissive microenvironment for cell engraftment.[60]
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Table 2. Published use of hydrogel therapies in ICH models. Outcomes refer to quantified histological or behavioral data of hydrogel group(s) which
are significantly altered compared with control groups. Abbreviations: bFGF, basic fibroblast growth factor; BMSCs, bone-marrow-derived mesenchymal
stem cells; BrdU, bromodeoxyuridine; DFO, deferoxamine mesylate; EGF, epidermal growth factor; Iba-1, ionized calcium-binding adapter molecule 1;
GFAP, glial fibrillary acidic protein; ICH, intracerebral hemorrhage; MH, minocyline hydrochloride; mNSS, modified neurological severity score; MPO,
myeloperoxidase; NeuN, hexaribonucleotide binding protein-3; nNOS, neuronal nitric oxide synthase; NPCs, neural progenitor cells; TNF-𝛼, tumour
necrosis factor alpha; TUNEL, terminal deoxynucleotidyl transferase; dUTP, nick end labeling.





Xu et al. 2020[92] Collagenase, mouse 3 days post-ICH Gelatin n/a ↑ Neuronal density (NeuN)
↓ Activated microglia (Iba-1) and astrocytes
(GFAP), release of interleukin-1𝛽 and TNF-𝛼
↑ Functional recovery assessed by neuroscore
Lim et al. 2020[56] Collagenase, rat 14 days post-ICH Gelatin and
hydrophenylproprionic
acid
EGF ↑ NPCs (Nestin+) migrating into cavity
↑ Functional recovery assessed by mNSS,
forelimb placing, and corner test scores
Gong et al. 2020





↓ Iron staining, brain atrophy, and brain water
content
↑ Proliferation (BrdU) at 14 days
↑ Functional recovery assessed by forelimb
placing and corner test scores
Zhu et al. 2019
a,b) [55] Autologous blood, rat 6 h post-ICH Keratin and N-isopropyl
acrylamide
DFO ↓ Iron staining, nonheme iron content, and brain
water content
↑ Functional recovery assessed by forelimb
placing and corner test scores
Luo et al. 2017
a,b) [57] Autologous blood +
aspiration at 4 h, rat
4 h post-ICH Keratose MH ↓ Iron staining, iron content, and brain water
content
↑ Functional recovery assessed by forelimb





at 3.5 h, mouse
3.5 h post-ICH RADA16–RGD/RADA16–
IKVAV mixc)
n/a ↓ Hematoma volume, microglia (Iba-1),
infiltrating macrophages (CD11b), C-jun, and
apoptosis (TUNEL)
↑ Neurons (NeuN) and neuron survival (nNOS)
↑ Functional recovery assessed by rotarod, grip
strength, and gait analysis
Sang et al. 2015
a,b) [45] Collagenase + aspiration
at 3.5 h, rat
3.5 h post-ICH RADA16-Ic) n/a ↓ Hematoma volume and brain water content
↓ Neutrophils (MPO+), microglia/macrophages
(CD68), and apoptosis (TUNEL) in
perihematomal area
Sun et al. 2016
a,b) [91] Collagenase + aspiration
at 3.5 h, mouse




n/a Unclear outcomes of hydrogel injection
a,b)
Studies by the same group
c)
Amino acid sequences for peptide hydrogels.
7. Considerations for Hydrogel Application in ICH
To the best of our knowledge, to date, only four groups have in-
vestigated hydrogel-based therapies in animal models of ICH,
demonstrating positive impacts on functional and histological
outcomes following intracerebral hydrogel injection (Table 2).
Consistent with the general ICH literature, the collagenase
model is the most widely used for these studies, with rats being
the predominant species, likely due to the ability to inject larger
gel volumes into the ICH cavity. Several of these studies aspi-
rate the hematoma within hours of ICH induction, filling the re-
sulting cavity with hydrogel, while others administer the hydro-
gel acutely (within 6 h) or chronically (after 14 days) after ICH
without aspiration. Composition of the hydrogel itself is varied;
some groups employ natural gels, composed of gelatin or ker-
atin, while others use SAPHs that are based on RADA (arginine,
alanine, and aspartate) amino acid repeats. Some of these stud-
ies have incorporated previously tested pharmacological agents
in the gels, including deferoxamine mesylate (DFO) and minocy-
line hydrochloride (MH), which have shown no benefit in clinical
trial when injected alone, suggesting that the synergistic effect of
the drug–hydrogel combination may benefit recovery. Given the
unique pathological features of ICH, it is critical to consider all
aspects of in vivo study design, from the time of administration
to the outcomes measured. These factors will now be discussed,
with considerations as to how research in IS and TBI may be
translatable to ICH studies.
8. Study Design: Time of Administration
Therapeutic interventions for brain injuries typically target
two distinct therapeutic windows. Neuroprotective therapies are
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given early (within hours) and aim to minimize tissue damage
and functional impairment, while regenerative therapies are typ-
ically delayed (days to weeks) and aim to promote tissue recovery
and restore physiological tissue architecture and function.[54] For
the purpose of this article, we define administration intervals as
follows: acute as within 24 h, subacute as between 2 and 5 days,
and chronic as beyond 5 days post-ICH.
The target and mechanism of action of new treatments must
be considered when determining the: i) timing and volume of
hydrogel administration, ii) timepoints for assessment, and iii)
primary outcome measures, as all will have a decisive role on the
conclusions that can be made from the study. The time of ad-
ministration is critical for the efficacy of the treatment. For exam-
ple, administration of hydrogel therapies targeting the detrimen-
tal inflammatory response may be more appropriate during the
acute and subacute stages of brain injury as tissue damage and
inflammation are prominent shortly following tissue insult.[61,62]
Conversely, transplantation of cell-laden hydrogels for tissue re-
pair in an environment rich in inflammatory cytokines, necrotic
tissue, blood-by-products, and degrading enzymes can compro-
mise the cells’ potential for integration and differentiation into
the local tissue.[62]
The small number of preclinical studies in ICH (Table 2)
are primarily focused on acute administration of hydrogels
with six out of eight studies administering the hydrogel within
6 h of ICH induction. Early hydrogel transplantation is preceded
by hematoma evacuation in four studies, while only one targets
the chronic window for tissue repair by transplanting hydrogels
in the ICH cavity 14 days after hemorrhage induction (Table 2). A
similar trend is observed in the literature of hydrogel studies in
TBI where many studies target the acute neuroinflammation
phase of TBI with hydrogels being administered immediately af-
ter TBI induction or within the first hours following injury. A
small number of studies administered hydrogels at 7 days post-
TBI.[63–65] A systematic review and meta-analysis conducted by
our group on in vivo studies using biomaterials in experimental
IS revealed that hydrogels are predominantly transplanted dur-
ing the chronic reparative phase. Most studies administered hy-
drogels days or weeks after stroke, while few studies investigated
hydrogel administration earlier than 24 h post-IS.[66] The differ-
ence in approaches for hydrogel treatment in IS versus ICH and
TBI is noteworthy and future studies in ICH should consider de-
layed treatment paradigms.
9. Study Design: Combination of Hydrogels with
Therapeutics
In ICH preclinical studies, hydrogels have been used
as scaffolds for regeneration[45,46] or as delivery systems
for therapeutics.[55–58] Approaches targeting unique aspects
of ICH include the combination of hydrogels with previously
tested drugs such as DFO[55] and MH,[57] which were delivered to
the lesion for sustained action within a keratin-based hydrogel.
DFO was more effective in reducing iron deposition and brain
edema when released from a hydrogel compared to DFO or
hydrogel alone.[55] Growth factors such as epidermal growth
factor (EGF)[56] and its combination with basic FGF (bFGF)[58]
have also been delivered using gelatin- and keratin-based hy-
drogels, respectively. All these approaches were combined by
Gong et al., who designed a core–shell hydrogel system con-
taining MH and poly(lactic-co-glycolic acid) nanoparticles loaded
with EGF and bFGF for bone-marrow-derived MSC delivery into
an ICH model. The core–shell system improved the viability of
transplanted cells and accelerated neurological recovery.[58]
Hydrogels have been extensively explored in IS and TBI stud-
ies as tools for delivering regenerative drugs, growth factors, or
cells. Notable examples include slowly released BDNF from a HA
hydrogel which reduced lesion volumes, improved performance
in motor function tests at nine weeks post-IS, and promoted
axonal sprouting and neuroblast migration, when compared
with bolus BDNF or hydrogel alone.[67] Additionally, chondroiti-
nase ABC stabilized in HA–methylcellulose blended hydrogels
attenuated the glial scar in an IS model by reducing chondroitin
sulfate proteoglycan levels at 28 days after injury.[68] NSCs and
EPCs transplanted either alone or together within a SAPH,
7 days post-TBI, reduced astrogliosis at the lesion site compared
to cells alone.[69] Cotransplants of NSCs and adipose-derived
stem cells in the same hydrogel reduced brain lesion volumes,
attenuated inflammation and glial scar formation, and improved
motor function following TBI, compared to gel alone groups.[70]
Therapeutic combinations that show potential in IS and TBI
may also prove beneficial in the context of ICH, given the shared
disease mechanisms and regenerative processes involved in
acute brain injuries. Additionally, multimodal therapies are yet
to be explored in the context of ICH, presenting an opportunity
to investigate cell-laden hydrogel therapies. Transplantation of
MSCs and NSCs in hydrogels has been proven beneficial in
preclinical studies of IS and TBI, thus may also hold promise in
aiding repair and regeneration post-ICH.
10. Study Design: Assessing Regeneration
Endogenous repair mechanisms, such as neurogenesis and an-
giogenesis, are important hallmarks of tissue repair for gauging
therapeutic efficacy of hydrogel interventions as both contribute
to functional recovery after acute brain injury.[71,72] While tissue
regeneration is associated with functional recovery after acute
brain injury, the direct relationship between the two has not yet
been fully elucidated. The assessment of functional recovery in
ICH using a variety of behavioral tests has been extensively ad-
dressed and published previously.[73–76]
At the tissue level, following an insult to the brain, resident
neural stem or progenitor cells (NSPCs) are recruited from the
neurogenic niches to the site of injury where they differenti-
ate into neurons and glial cells in order to compensate for the
lost cells.[77,78] For example, in IS, injection of a HA-based hy-
drogel alone led to increased NSPC proliferation in the neuro-
genic niche of the brain, which were then shown to migrate
into the core of the stroke lesion.[79] To stimulate endogenous
regenerative responses in TBI, a Matrigel scaffold with a gradi-
ent of semaphorin 3A was delivered, which led to an increase in
migrating neuroblasts and NSPCs within the lesion compared to
TBI alone.[80] Although not as well characterized, a similar neuro-
genic response occurs following ICH.[81–83] To further stimulate
this response in experimental ICH, Lim et al. combined a gelatin-
based hydrogel with EGF and demonstrated that NSPCs could
migrate into the hydrogel scaffold and differentiate into multiple
neuronal lineages.[56]
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Restorative neurogenesis is known to be coupled with simul-
taneous angiogenic processes.[71,72] NSPCs residing in the neu-
rogenic niches are closely associated with the vasculature. Blood
vessel remodeling via angiogenic and vasculogenic mechanisms
facilitates neurogenesis and synaptogenesis as NSPCs have been
demonstrated to rely on the vasculature for migration to the in-
jury site.[84–86] After ischemic injury, angiogenesis begins 4 to
7 days after onset, mainly at the border of the ischemic core.[87]
However, the process of neurogenesis does not start until around
2 weeks after stroke. It is thought that post-ischemic angiogenesis
may have a role in axonal outgrowth through vascular endothe-
lial growth factor (VEGF) and laminin/𝛽1-integrin signaling. En-
dothelial cells orchestrate vascular remodeling and organize into
new blood vessels to repair the damaged vascular network and
re-establish blood flow to the site of injury. New blood vessels
formed early after stroke are also thought to increase the prolif-
eration of NSPCs and support their recruitment to the site of in-
jury, by providing a scaffold for migration as well as supplying
oxygen and nutrients. Finally, tissue oxygenation in the ischemic
core triggered by angiogenesis is thought to increase the differ-
entiation of recruited NSPCs into mature neuronal cell types.[88]
These processes are thought to contribute to functional recovery.
The decoupling of these mechanisms is a common feature of
acute brain injury and therefore therapeutic strategies targeting
these reparative processes may hold promise.[71,72] For instance,
delivery of a HA hydrogel with encapsulated VEGF into the cav-
ity resulted in de novo blood vessel formation in both IS and
TBI,[44,89] and the elaboration of functional axonal networks along
the novel vasculature in regions of previously lost tissue in IS.[44]
Additionally, injection of the SAPH “SLanc” after TBI caused a
significant upregulation of canonical markers of angiogenesis,
including von Willebrand factor and VEGF receptor 2 compared
with TBI control animals.[90]
To date, studies testing hydrogels in ICH have assessed tissue
responses by observing changes in mature neural markers,[46]
by exploring immune cell infiltration[45,46,56] or by assessing
gross morphological changes such as ventricular enlargement
and cavity volume.[45,46] While global analysis of the effect of
hydrogel injection on the surrounding tissue is important, future
work exploring the effect on endogenous repair mechanisms,
for instance, on the recruitment of NSPCs and the expression
of key angiogenic markers, will be of great value to the ICH
field. However, it is worth noting that while hydrogels for neural
repair are often designed to initiate neuronal cell differentiation,
angiogenesis precedes and facilitates subsequent neurogenesis
and is likely to occur under different conditions. In addition,
hydrogels will undergo complex dynamic remodeling after in
vivo implantation. Therefore, it is challenging to determine the
exact hydrogel mechanical properties needed for distinct but in-
terdependent repair processes during the course of regeneration.
11. Discussion of Unique Considerations for ICH
11.1. Hydrogel Properties
When designing hydrogels for ICH applications, many of the de-
sirable properties for application in other acute brain injuries also
apply. For instance, the candidate hydrogel should: i) be injectable
and be able to gel in situ for minimally invasive administration,
ii) have mechanical properties comparable to brain tissue, iii) be
biocompatible and biodegradable to support de novo tissue for-
mation, and iv) be made of an appropriate material with a porous
structure that allows host and transplanted cell infiltration, adhe-
sion, and survival, as well as circulation of metabolites. These key
features have been largely addressed in hydrogel studies in ICH
so far (Table 2).
Hydrogel properties are largely dependent on the material
used for hydrogel formulation. The majority of studies in ICH
use protein or peptide-based hydrogels[45,46,91] due to their fa-
vorable properties, facilitating in vivo degradation or gelation ei-
ther via physical (SAPHs[45,46,91]) or chemical cross-linking reac-
tions (gelatin-based hydrogels[56,92]). Hydrogel functionalization
has also been explored to enhance cell adhesion; studies using
synthetic SAPHs have reported increased cell adhesion to the hy-
drogel after incorporation of ECM-based adhesion motifs such as
IKVAV (laminin) or RGD (fibronectin) peptides.[46,91] Hydrogel
functionalization may also improve the survival of transplanted
cells and host tissue and modulate the inflammatory response,
leading to improved functional recovery.[46] However, it is worth
noting that natural hydrogels such as collagen and gelatin in-
herently contain endogenous cell adhesion motifs, thus, further
functionalization may not be required.
Tuning the mechanical characteristics of the hydrogel such as
stiffness and porosity is often necessary to ensure an appropri-
ate tissue response and prevent damage to healthy tissue. For ex-
ample, four studies evaluating hydrogels for ICH reported hy-
drogel stiffness in the range of normal brain tissue (10–1000
Pa).[56,58,91,92] The degree of scaffold porosity is also critical for
facilitating cell invasion and circulation of nutrients and metabo-
lites in the transplanted hydrogel. Several ICH papers assessing
hydrogel porosity by scanning electron microscopy[55,57,58,92] re-
ported the presence of interconnected network of pores with sizes
between 20 and 100 µm, which falls within the range of mam-
malian cell diameter to facilitate cell infiltration. Conversely, hy-
drogels with smaller pore sizes, as reported for RADA-I-based
SAPH (5–200 nm), may preclude or hinder cell infiltration.[93]
Hydrogel injectability is another desirable quality for transplan-
tation and the majority of published studies using hydrogels in
ICH use injectable hydrogels that gel in situ. Injectable hydro-
gels permit minimally invasive administration and allow gels to
conform to the hematoma cavity space, minimizing pressure on
surrounding brain structures and healthy tissue.
In addition to physical characteristics, biological properties
of hydrogels such as biocompatibility and the ability to inter-
act with the surrounding tissue can also be tailored for in vivo
applications. Hydrogels administered after ICH were shown to
be well tolerated by the host tissue as no studies reported an
increase in inflammation, cell apoptosis, or scarring. For in-
stance, SAPHs led to decreased cell apoptosis and reduced in-
filtration of inflammatory cells after ICH,[45,46] while adminis-
tration of a gelatin hydrogel led to lower activated immune cell
infiltration when compared to the vehicle group.[92] Following
administration into the brain, hydrogel interaction with trans-
planted and endogenous cells is critical for regeneration and
functional recovery. In ICH, an EGF-containing hydrogel was
shown to improve NSPC recruitment compared to bolus EGF[56]
and administration of a RADA-based SAPH decreased mi-
croglial and macrophage infiltration,[46] while administration of a
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drug-containing hydrogel led to improved graft BMSC viability
and improved host neuronal cell survival.[58] Finally, examination
of material interaction with the hematoma revealed that the hy-
drogel may prevent the formation of a visible hemosiderin scar,
which is a common feature of ICH pathology.[92] Hydrogels such
as RADA-based hydrogels may also reduce the hematoma vol-
ume, revealing possible hemostatic properties.[46]
Overall, hydrogel studies in ICH models to date have consid-
ered the impact of hydrogel properties on a variety of functional
and histological outcomes. However, given the limited number
of published studies and groups investigating hydrogels for ICH,
identifying an “ideal” hydrogel candidate for a regenerative ther-
apy is challenging, since at this stage, there is no clear consensus
on the best material or encapsulated agents to use.
11.2. Applications in Experimental ICH
To date, preclinical ICH studies testing hydrogels have used the
collagenase, autologous blood, or FeCl2 models (Table 2). Al-
though no animal model can fully recapitulate the complex etiol-
ogy of human ICH, each model can provide important informa-
tion on the pathophysiological processes that could be therapeuti-
cally targeted. When designing a study, it is important to consider
how model selection could influence the outcomes of hydrogel
injection. For example, the collagenase model causes more se-
vere BBB disruption, cell death, and peripheral immune cell in-
filtration than the autologous blood model,[94] which may influ-
ence the inflammatory response to the material and how quickly
the hydrogel is degraded. MacLellan et al. also reported quicker
resolution of neurological deficits in the autologous blood model,
suggesting that studies investigating long-term outcomes should
consider using the collagenase model.[94] Nonetheless, both mod-
els produce consistent hemorrhages with pathophysiological el-
ements observed in human ICH, with each model having ad-
vantages depending on the research question to be answered.
The FeCl2 model mimics iron-induced toxicity and the resultant
edema after ICH,[95] but does not model the rise in ICP caused by
hematoma mass effects and thus may be an inappropriate model
for optimizing the time and volume of hydrogel administration.
While a number of hydrogel candidates tested in IS and TBI
are now being explored in ICH, the unique environment of the
ICH cavity, including the presence of free iron and peripheral im-
mune cell populations, may differentially affect the therapeutic
efficacy of injected hydrogels. In addition, the majority of ICH
models result in striatal lesions, whereas TBI models predom-
inantly trigger injury to the cortex[96] and IS models can cause
damage to both subcortical and cortical areas, depending on the
severity and location of the arterial occlusion.[97] As a result of
differences in injury proximity to the neurogenic zones, the type
of neurological deficit caused, and the tissue architecture of the
affected region, therapeutic strategies employed in one type of
acute brain injury may not necessarily be translatable across dis-
ease models.
When considering clinical translation for ICH, the proven
safety of minimally invasive hematoma aspiration could present
an opportunity for hydrogel transplantation.[29] Indeed, the Hem-
orrhagic Stroke Academia Industry (HEADS) report outlining
recommendations and priorities for future translational ICH re-
search encouraged further study of “multimodal therapy” such
as clot evacuation combined with administration of a restorative
therapy.[98] However, as discussed, administration of hydrogels or
other therapeutic agents must be carefully timed alongside ICH
progression, to maximize the safety and efficacy of the therapy.
Alternatively, hydrogel administration at chronic timepoints may
be safe without the need for hematoma evacuation. Moreover, the
neutral outcome of early minimally invasive surgery and the un-
successful trials of multiple interventions aimed at reducing pri-
mary injury cast doubt on the early intervention or “neuroprotec-
tive” approach in ICH.[28] Studies exploring hydrogel administra-
tion at chronic timepoints in combination with pro-regenerative
therapies are therefore a potential alternative approach.
12. Conclusions and Future Perspectives
Although there are differences in the pathophysiological features
of IS, TBI, and ICH, some mechanisms are shared, including
brain tissue repair processes. Given these commonalities, the ex-
tensive literature in IS and TBI can inform and advance the newly
emerging field of hydrogel use in ICH. The wide variety of hydro-
gels tested in IS and TBI models gives scope to repurpose these
materials for ICH applications, perhaps with ICH-specific thera-
peutics for a combinatorial approach. Additionally, cell therapies
administered with hydrogels have been extensively explored in
IS and TBI and may also be worth considering in ICH. Studies
in IS and TBI have also revealed some beneficial effects of hydro-
gel implantation on endogenous repair processes, and therefore
assessment of angiogenic and neurogenic responses following
hydrogel administration may be valuable in the context of ICH.
Conversely, the unique features of ICH pathology may pre-
clude direct translation of methods from IS and TBI research
and require a more tailored approach. In particular, the volume
and timing of hydrogel administration must be carefully consid-
ered, given the space-occupying nature of the ICH lesion. Fur-
thermore, several aspects of hydrogel implantation such as in
vivo hydrogel degradation and long-term local and systemic ef-
fects are yet to be extensively explored in acute brain injury, and
therefore require further study before clinical translation. Finally,
the proven clinical safety of surgical intervention after ICH may
represent an exciting opportunity in terms of the feasibility and
translational potential of hydrogel-based therapeutics.
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